Benefit from Adjuvant TKIs Versus TKIs Plus Chemotherapy in <i>EGFR</i>-Mutant Stage III-pN2 Lung Adenocarcinoma

Benefit from Adjuvant TKIs Versus TKIs Plus Chemotherapy in <i>EGFR</i>-Mutant Stage III-pN2 Lung Adenocarcinoma

Background: Recent studies have demonstrated benefits from adjuvant tyrosine-kinase inhibitors (TKIs) compared with chemotherapy in non-small cell lung cancer. We launched a multi-center retrospective study to evaluate the efficacy and toxicity of adjuvant TKIs with or without chemotherapy in epider...

Full description

Bibliographic Details
Main Authors: Qiwen Li, Li Ma, Bo Qiu, Yuzhi Wen, Wenhua Liang, Wanming Hu, Naibin Chen, Tian Zhang, Shuangbing Xu, Lingjuan Chen, Minzhang Guo, Yi Zhao, Songran Liu, Jinyu Guo, Junye Wang, Siyu Wang, Xin Wang, Qingsong Pang, Hao Long, Hui Liu
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Current Oncology
Subjects:
lung adenocarcinoma
N2
<i>EGFR</i> mutation
adjuvant TKIs
chemotherapy
Online Access:https://www.mdpi.com/1718-7729/28/2/135

Internet

https://www.mdpi.com/1718-7729/28/2/135

Similar Items